Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation.
BACKGROUND
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in children. No treatment has been shown to significantly improve the clinical outcome of patients with this infection. Recent evidence suggests that oxidative stress could play an important role in the pathogenesis of acute and chronic lung inflammatory diseases. We do not known whether RSV induces pulmonary oxidative stress and whether antioxidant treatment can modulate RSV-induced lung disease.


OBJECTIVE
To investigate the effect of antioxidant administration on RSV-induced lung inflammation, clinical disease, and airway hyperreactivity (AHR).


METHODS
BALB/c mice were infected with 10(7) plaque-forming units of RSV, in the presence or absence of orally administered butylated hydroxyanisole (BHA), an antioxidant. Malondialdehyde and 4-hydroxynonenal were measured in bronchoalveoar lavage (BAL) by colorimetric assay. Cytokines and chemokines were measured in BAL by Bio-Plex and leukotrienes were measured by enzyme-linked immunosorbent assay. AHR to methacholine challenge was measured by whole-body plethysmography.


RESULTS
BHA treatment significantly attenuated RSV-induced lung oxidative stress, as indicated by the decrease of malondialdehyde and 4-hydroxynonenal content in BAL of RSV-infected mice. RSV-induced clinical illness and body weight loss were also reduced by BHA treatment, which inhibited neutrophil recruitment to the lung and significantly reduced pulmonary cytokine and chemokine production after RSV infection. Similarly, antioxidant treatment attenuated RSV-induced AHR.


CONCLUSIONS
Modulation of oxidative stress represents a potential novel pharmacologic approach to ameliorate RSV-induced acute lung inflammation and potentially prevent long-term consequences associated with RSV infection, such as bronchial asthma.
Castro
Shawn Monique
SM
Department of Pediatrics, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555-0366, USA.
Guerrero-Plata
Antonieta
A
Suarez-Real
Giovanni
G
Adegboyega
Patrick A
PA
Colasurdo
Giuseppe N
GN
Khan
Amir M
AM
Garofalo
Roberto P
RP
Casola
Antonella
A
D000447:Aldehydes / Q000032:analysis; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002083:Butylated Hydroxyanisole / Q000494:pharmacology; D018925:Chemokines / Q000032:analysis; D003124:Colorimetry; D016207:Cytokines / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007249:Inflammation / Q000503:physiopathology*; D015289:Leukotrienes / Q000032:analysis; D008168:Lung / Q000502:physiology*; D008315:Malondialdehyde / Q000032:analysis; D051379:Mice; D008807:Mice, Inbred BALB C; D018384:Oxidative Stress / Q000187:drug effects; D012130:Respiratory Hypersensitivity / Q000503:physiopathology; D018357:Respiratory Syncytial Virus Infections / Q000503:physiopathology*
D000447:Aldehydes; D000975:Antioxidants; D018925:Chemokines; D016207:Cytokines; D015289:Leukotrienes; D002083:Butylated Hydroxyanisole; D008315:Malondialdehyde; C027576:4-hydroxy-2-nonenal